Among them, IL-17A and IL-23 have emerged as pivotal pathogenic molecules in psoriasis, and immunomodulation with biologics aimed at targeting them has resulted in substantial improvement in the disease symptoms and quality of life for patients [30,31]. The gene discussed is IL17A; the disease is psoriasis.